Skip to content

APPART study

APpendix derived PAncreatic cancer Reactive T-lymphocytes

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON20200
Enrollment
50
Registered
2019-02-25
Start date
2019-02-15
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic ductal adenocarcinoma (PDAC)

Interventions

Peripheral venous blood draws, appendectomy during standard of care (laparoscopic) surgery, liver and peritoneal biopsies if metastases are visualized during staging laparoscopy

Sponsors

Department of Surgery, Erasmus Medical Center Rotterdam
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged 18 years or older with treatment naïve pancreatic ductal adenocarcinoma who will either undergo staging laparoscopy for locally advanced disease, or tumor resection for (borderline) resectable disease.

Exclusion criteria

Exclusion criteria: prior appendectomy, prior malignancy within the past 5 years, prior chemotherapy or radiotherapy within the past 5 years, pregnancy, participation in the PREOPANC-2 trial.

Design outcomes

Primary

MeasureTime frame
The level of PDAC-specific oncolytic activity of vermiform appendix derived T lymphocytes

Secondary

MeasureTime frame
Identification of - PDAC specific antigens - appendix fecal microbiome diversity - molecular immune landscapes in the vermiform appendix sana from patients with PDAC compared to controls - differential T-cell and B-cell receptor repertoires in peripheral blood lymphocytes vs lymphocytes from the vermiform appendix, in patients with PDAC.

Contacts

Public ContactEveline Vietsch

Erasmus Medisch Centrum Rotterdam

e.vietsch@erasmusmc.nl+31107044331

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)